--- title: "Silexion Therapeutics Announces Warrant Inducement Financing Agreement" type: "News" locale: "en" url: "https://longbridge.com/en/news/286622270.md" description: "Silexion Therapeutics has entered a warrant inducement financing agreement, allowing holders of 1,995,092 existing warrants to exercise them at $0.50 per share for new Series C and D warrants. The company anticipates $1.0 million in gross proceeds and has engaged H.C. Wainwright & Co. as the placement agent. The new warrants will have specific terms and protections, while the current analyst rating for SLXN stock is a Buy with a $6.00 price target, though Spark's AI Analyst rates it as Neutral due to financial concerns." datetime: "2026-05-15T22:44:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286622270.md) - [en](https://longbridge.com/en/news/286622270.md) - [zh-HK](https://longbridge.com/zh-HK/news/286622270.md) --- # Silexion Therapeutics Announces Warrant Inducement Financing Agreement ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Silexion Therapeutics ( (SLXN) ) just unveiled an update. On May 15, 2026, Silexion Therapeutics entered into an inducement agreement with holders of 1,995,092 existing warrants, who agreed to exercise those warrants for cash at a reduced price of $0.50 per share in exchange for new Series C and Series D warrants to purchase up to 3,990,184 additional ordinary shares at the same exercise price. The company expects about $1.0 million in gross proceeds before fees, has engaged H.C. Wainwright & Co. as exclusive placement agent with a mix of cash and warrant compensation, and has imposed short-term restrictions on new share issuances and longer-term limits on variable rate financings, while committing to register the resale of the new warrant shares under U.S. securities laws. The new warrants and related placement agent warrants are being issued in a private placement exempt from registration, carry five-year and two-year terms respectively for the Series C and Series D tranches starting after shareholder approval and resale registration effectiveness, and include ownership caps, cashless exercise mechanics if no effective resale registration exists, and fundamental transaction protections such as Black-Scholes-based cash redemption on change of control. These terms, along with the absence of an expected trading market for the warrants and the company’s agreement to maintain an effective resale registration statement, shape the instruments as a targeted capital-raising and balance sheet tool with defined protections and limitations for both Silexion and its accredited investors. The most recent analyst rating on (SLXN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page. **Spark’s Take on SLXN Stock** According to Spark, TipRanks’ AI Analyst, SLXN is a Neutral. The score is held down primarily by weak financial durability (no revenue and continued cash burn) and bearish technicals (below all major moving averages with negative MACD). Positive pipeline/regulatory progress and manufacturing readiness provide support, but not enough to offset funding dependence and the current downtrend. To see Spark’s full report on SLXN stock, click here. **More about Silexion Therapeutics** Silexion Therapeutics Corp. operates in the biotechnology and pharmaceutical sector, issuing ordinary shares and warrants to fund its operations and development activities. The company accesses capital markets through public offerings, inducement warrant transactions and private placements, targeting institutional accredited investors within the U.S. securities framework. **Average Trading Volume:** 80,222 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** $2.03M See more insights into SLXN stock on TipRanks’ Stock Analysis page. ### Related Stocks - [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md) ## Related News & Research - [Silexion Therapeutics reports Q4 results](https://longbridge.com/en/news/279492728.md) - [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md) - [Maxim Group Sticks to Their Buy Rating for Silexion Therapeutics (SLXN)](https://longbridge.com/en/news/284605688.md) - [Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress](https://longbridge.com/en/news/274679610.md) - [Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary](https://longbridge.com/en/news/286619052.md)